AGL 40.22 Increased By ▲ 0.21 (0.52%)
AIRLINK 127.00 Decreased By ▼ -0.99 (-0.77%)
BOP 6.62 Increased By ▲ 0.02 (0.3%)
CNERGY 4.50 Decreased By ▼ -0.10 (-2.17%)
DCL 8.61 Increased By ▲ 0.13 (1.53%)
DFML 41.65 Increased By ▲ 0.17 (0.41%)
DGKC 87.00 Increased By ▲ 0.42 (0.49%)
FCCL 32.30 Increased By ▲ 0.16 (0.5%)
FFBL 65.25 Decreased By ▼ -0.17 (-0.26%)
FFL 10.20 Decreased By ▼ -0.05 (-0.49%)
HUBC 109.97 Decreased By ▼ -0.52 (-0.47%)
HUMNL 14.63 Decreased By ▼ -0.12 (-0.81%)
KEL 5.13 No Change ▼ 0.00 (0%)
KOSM 7.50 Increased By ▲ 0.38 (5.34%)
MLCF 41.58 Decreased By ▼ -0.07 (-0.17%)
NBP 59.60 Decreased By ▼ -0.49 (-0.82%)
OGDC 194.50 Decreased By ▼ -0.19 (-0.1%)
PAEL 28.15 Increased By ▲ 0.20 (0.72%)
PIBTL 7.82 Decreased By ▼ -0.18 (-2.25%)
PPL 152.30 Increased By ▲ 1.13 (0.75%)
PRL 26.51 Decreased By ▼ -0.37 (-1.38%)
PTC 16.07 Increased By ▲ 0.07 (0.44%)
SEARL 79.54 Increased By ▲ 1.34 (1.71%)
TELE 7.49 Increased By ▲ 0.10 (1.35%)
TOMCL 35.49 Decreased By ▼ -0.18 (-0.5%)
TPLP 8.24 Increased By ▲ 0.33 (4.17%)
TREET 16.04 Increased By ▲ 0.15 (0.94%)
TRG 52.80 Increased By ▲ 0.04 (0.08%)
UNITY 26.79 Increased By ▲ 0.24 (0.9%)
WTL 1.25 Decreased By ▼ -0.02 (-1.57%)
BR100 9,910 Decreased By -10.5 (-0.11%)
BR30 30,787 Increased By 35.1 (0.11%)
KSE100 93,410 Increased By 185.5 (0.2%)
KSE30 28,950 Increased By 64.9 (0.22%)

imageLONDON: The world's first life-saving gene therapy for children, developed by GlaxoSmithKline and Italian scientists, was approved for sale in Europe on Friday, in a step forward for the pioneering technology to fix faulty genes.

Called Strimvelis, it is designed for a tiny number of children with ADA Severe Combined Immune Deficiency (ADA-SCID).

SCID is sometimes known as "bubble baby" disease, since those born with it have immune systems so weak they must live in germ-free environments.

Strimvelis is the second gene therapy to be approved in Europe, after UniQure's Glybera, which treats a rare adult blood disorder.

Glybera made history in 2014 as the first drug to carry a $1 million price tag.

GSK has not so far revealed how much its product will cost but a source close to the company said last month it would be "very significantly less than $1 million".

The EU approval for GSK's treatment had been expected, following a positive opinion from the European Medicines Agency last month.

The US Food and Drug Administration has yet to approve any gene therapies but a growing number of US biotech companies have products in development.

Copyright Reuters, 2016

Comments

Comments are closed.